Shilpa Group announced the commissioning of an integrated Good Manufacturing Practice (GMP) facility for antibody-drug conjugate (ADC) drug substances. The move adds a new dimension to the company's long-standing expertise in manufacturing highly potent compounds.
The facility is purpose-built for ADC drug substances, which combine antibodies with potent cytotoxic agents to target cancer cells. This follows a broader industry trend of expanding manufacturing capacity for advanced biotherapeutics.
Shilpa's existing portfolio includes capabilities in highly potent active pharmaceutical ingredients (HPAPIs), and this ADC facility represents a strategic expansion into finished drug product manufacturing for biologics. The facility is now operational and available for client partnerships.
While the company did not disclose specific client contracts or production volumes, the announcement positions Shilpa to capture growing demand in the ADC contract development and manufacturing organization (CDMO) market.
No timeline for regulatory approvals or specific indications were provided, and it remains unclear how quickly this capacity will translate into revenue. Industry observers note that ADC manufacturing requires high technical expertise and that operational scale-up may take quarters to achieve.